Editor's note: Do the benefits of PSA screening outweigh therisks? Watch video of a roundtable discussion, participate ina poll, and contribute your comments in our Clinical Directionsfeature — Screening for Prostate Cancer. Commenting closesApril 1, 2009.
In the United States, most men over the age of 50 years havehad a prostate-specific–antigen (PSA) test,1 despite theabsence of evidence from large, randomized trials of a net benefit.Moreover, about 95% of male urologists and 78% of primary carephysicians who are 50 years of age or older report that theyhave had a PSA test themselves,2 a finding that suggests theyare practicing what they preach. And indeed, U.S. death ratesfrom prostate cancer have fallen about 4% per year since 1992,five years after the introduction of PSA testing.3 Perhaps theanswer to the PSA . . . [Full Text of this Article]
Source Information
From Massachusetts General Hospital and Harvard Medical School, Boston.
This article (10.1056/NEJMe0901166) was published at NEJM.org on March 18, 2009.
Related Letters:
Prostate-Cancer Screening
Catalona W. J., Preston S. H., Cooperberg M. R., Carroll P. R., Ojha R. P., Thertulien R., Fischbach L. A., Izmirlian G., Dubben H.-H., Andriole G. L., Miller A. B., Berg C. D., the PLCO Project Team , Schröder F. H., Roobol M., Moss S., the ERSPC Investigators
Extract |
Full Text |
PDF
N Engl J Med 2009;
361:202-206, Jul 9, 2009.
Correspondence
This article has been cited by other articles:
Brawley, O. W., Gansler, T.
(2010). Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline. CA Cancer J Clin
0: caac.20067v1-NA
[Full Text]
Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., Print, C.
(2010). Predictive and prognostic molecular markers for cancer medicine. Therapeutic Advances in Medical Oncology
2: 125-148
[Abstract]
Hall, F. M.
(2010). Identification, Biopsy, and Treatment of Poorly Understood Premalignant, in Situ, and Indolent Low-Grade Cancers: Are We Becoming Victims of Our Own Success?. Radiology
254: 655-659
[Full Text]
Brandt, A., Bermejo, J. L., Sundquist, J., Hemminki, K.
(2009). Age at Diagnosis and Age at Death in Familial Prostate Cancer. The Oncologist
14: 1209-1217
[Abstract][Full Text]
Braillon, A.
(2009). Prostate screening in France. BMJ
339: b4285-b4285
[Full Text]
Sanda, M. G., Kaplan, I. D.
(2009). Prostate Cancer Screening and Surveillance--Reply. JAMA
302: 1529-1530
[Full Text]
Marshall, J. R.
(2009). Keeping Our Eye on the Ball: The American Society of Preventive Oncology in 2009. Cancer Epidemiol. Biomarkers Prev.
18: 2796-2802
[Full Text]
Sturgeon, C M, Lai, L C, Duffy, M J
(2009). Serum tumour markers: how to order and interpret them. BMJ
339: b3527-b3527
[Full Text]
Law, M.
(2009). What now on screening for prostate cancer?. J Med Screen
16: 109-111
[Full Text]
Nelson, W. G., De Marzo, A. M., Yegnasubramanian, S.
(2009). Epigenetic Alterations in Human Prostate Cancers. Endocrinology
150: 3991-4002
[Abstract][Full Text]
KLEIN, E. A.
(2009). What's new in prostate cancer screening and prevention?. Cleveland Clinic Journal of Medicine
76: 439-445
[Abstract][Full Text]
Catalona, W. J., Preston, S. H., Cooperberg, M. R., Carroll, P. R., Ojha, R. P., Thertulien, R., Fischbach, L. A., Izmirlian, G., Dubben, H.-H., Andriole, G. L., Miller, A. B., Berg, C. D., the PLCO Project Team, , Schroder, F. H., Roobol, M., Moss, S., the ERSPC Investigators,
(2009). Prostate-cancer screening.. NEJM
361: 202-203
[Full Text]
Pavlou, M., Diamandis, E. P.
(2009). The Search for New Prostate Cancer Biomarkers Continues. Clin. Chem.
55: 1277-1279
[Full Text]
Goodwin, P. J., Sridhar, S. S.
(2009). Health-Related Quality of Life in Cancer Patients--More Answers but Many Questions Remain. JNCI J Natl Cancer Inst
101: 838-839
[Full Text]
(2009). PSA Screening: Initial Reports from Two Randomized Trials. JWatch General
2009: 1-1
[Full Text]
Previous
